Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

“Responsive regulation” has been proposed to offset pharmaceutical industry illicit behaviour in areas such as drug marketing based on self- regulation backed up with threats of government sanctions. We explore the efficacy of responsive regulation by tracing recent investigations by the UK pharmaceutical industry self-regulatory authority into the firm Astellas’s illicit promotion of a top-selling prostate cancer drug. Using documentary data, we reveal a ruthless company culture reflected in the illicit, so-called off-label promotion across Europe and the deceptive “impression management” by company managers during the course of investigations in the UK. We argue for a more probing, adversarial and government-led regulatory approach instead of the self-regulatory approach that shields breaching companies from enforcement actions and associated public scrutiny.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • King's College London
  • University of Bath
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Övrig annan samhällsvetenskap

Nyckelord

Originalspråkengelska
Tidskrift Journal of White Collar and Corporate Crime
StatusE-pub ahead of print - 2020 nov 6
PublikationskategoriForskning
Peer review utfördJa

Nedladdningar

Ingen tillgänglig data

Relaterad forskningsoutput

Deborah Cohen, Shai Mulinari & Piotr Ozieranski, 2019 jul 2, I: BMJ: British Medical Journal. 366, 1453.

Forskningsoutput: TidskriftsbidragLetter

Visa alla (1)

Related projects

Shai Mulinari, Piotr Ozieranski & Lawrence King

Swedish Council for Working Life and Social Research (Forte)

2017/01/012021/12/31

Projekt: ForskningIndividuellt forskningsprojekt

Visa alla (1)